Table 6.
Previous studies describing patients with UE compared with those with PE
| Author | Numbers | OS/DSS | MFS | LRFS | Variables significant different between two groups | ||||
|---|---|---|---|---|---|---|---|---|---|
| PE | UE | PE | UE | PE | UE | PE | UE | ||
| Chui et al. [3] | 19 | 60 | 74%* | 98%* | 57%* (event-free) | 98%* (event-free) | NA | NA | Site, size |
| Potter et al. [12] | 139 | 64 | 60% | 74% | NA | NA | 90%* | 64%* | Size, depth, microscopic margins, flap or FSG coverage, chemotherapy, followup periods |
| Temple et al. [15] | 17 | 18 | NA | NA | NA | NA | NA | NA | Delay in receiving treatment, free flaps, perioperative complications |
| Lewis et al. [8] | 685 | 407 | 70%* | 88%* | 63%* | 83%* | NA | NA | Size, depth microscopic margins |
| Thacker et al. [16] | 23 | 29 | 80% | 73% | NA | NA | 91% | 79% | Free flap, radiotherapy |
| Arai et al. [current study] | 128 | 63 | 86% | 96% | 71% | 86% | 85% | 92% | Size, depth, flap or FSG coverage, chemotherapy, intraoperative blood loss |
* Significant difference between cohorts; OS = 5-year overall survival; DSS = 5-year disease-specific survival; MFS = 5-year metastasis-free survival; LRFS = 5-year local recurrence-free survival; PE = planned excision; UE = unplanned excision; NA = not available, no accurate data described in the articles; FSG = free skin graft.